Does a change to long-acting antianginals provide better symptom control, treatment satisfaction, and quality of life?
Maniscalco
M M
MM
University of North Carolina, Chapel Hill, NC, USA. Warren_Newton@med.unc.edu
Newton
W
W
D000203:Activities of Daily Living; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy* / Q000523:psychology*; D001262:Atenolol / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004110:Diltiazem / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D005996:Nitroglycerin / Q000627:therapeutic use*; D017060:Patient Satisfaction; D017410:Practice Guidelines as Topic; D011788:Quality of Life; D012107:Research Design / Q000592:standards; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000318:Adrenergic beta-Agonists; D003692:Delayed-Action Preparations; D014665:Vasodilator Agents; D001262:Atenolol; D004110:Diltiazem; D005996:Nitroglycerin